SCHEMBL21392882

SCHEMBL21392882

C=CC(=O)NCc1ccc(C(=O)Nc2ccccc2Oc2ccc(OCC)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
CACNA1H O95180 3/20 0.52
CACNA1B Q00975 1/20 0.52
NPC1 O15118 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HDAC1 Q13547 1/20 0.49
EPHX2 P34913 1/20 0.48
NR1H4 Q96RI1 1/20 0.48
HTT P42858 1/20 0.48
GAA P10253 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HPGD P15428 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8476285 0.80 MEN1 (0.60) RAB9AMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL8995961 0.74 MEN1 (0.60) RAB9AMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL7117307 0.74 RAB9A (0.69) RAB9AMEN1KMT2ACACNA1HCACNA1B
SCHEMBL10696975 0.73 POLB (0.59) RAB9AMEN1KMT2ANPC1HDAC1
SCHEMBL14523819 0.71 RAB9A (0.63) RAB9AMEN1KMT2ANPC1HDAC1
SCHEMBL2024309 0.70 CACNA1H (0.54) RAB9AMEN1KMT2ACACNA1HCACNA1B
SCHEMBL11927835 0.70 TGM2 (0.63) RAB9AMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL8089567 0.69 KMT2A (0.50) RAB9AMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL27716717 0.69 CACNA1H (0.60) RAB9AMEN1KMT2ACACNA1HCACNA1B
SCHEMBL9130894 0.69 LMNA (0.59) RAB9AMEN1KMT2ACACNA1HCACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 US disclosed
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 US disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
WO-2019183600-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-09-26 WO disclosed
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY FRONTIER MEDICINES CORPORATION 2019-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, BECN1, SQSTM1 RAB9A 223/4885MEN1 4319/4885KMT2A 3168/4885
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES RNF114, RNF4, RNF168 RAB9A 2224/4885MEN1 2638/4885KMT2A 501/4885
US-11666661-B2 Methods and compounds for targeted autophagy ATG7, BECN1, SQSTM1 RAB9A 223/4885MEN1 4319/4885KMT2A 3168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.